13F Holdings
中文EN

MDXH MDxHealth SA IFRS Annual reports only

Services-Medical Laboratories · Nasdaq · SEC CIK 1872529

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY19.8%
TTM net income YoY12.0%
TTM EPS YoY42.2%
Revenue 3-yr CAGR42.8%
Net income 3-yr CAGR—

Margins

Gross margin64.5%
Operating margin-13.4%
Net margin-31.1%
FCF margin-3.1%
EBITDA margin—

Returns

ROE-2,440.4%
ROA-22.0%
ROIC (approx.)-41.8%
Asset turnover0.71x

Leverage & solvency

Liabilities / assets108.2%
Debt / equity—
Current ratio1.08x
Interest coverage-18.33x

Cash quality & payout

Operating cash flow / net income0.07x
Accruals ratio-20.5%
Payout ratio—
Capex / revenue1.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$107.88M$90.05M$70.19M$37.05M$22.24M
Cost of revenue$38.24M$34.91M$26.26M$17.84M$11.68M
Gross profit$69.63M$55.14M$43.93M$19.22M$10.56M
R&D expense$10.35M$10.55M$6.38M$5.50M$5.59M
SG&A expense$26.93M$22.80M$23.01M$23.31M$13.91M
Operating income-$14.41M-$24.72M-$27.33M-$37.90M-$26.84M
Interest expense$786,000$384,000$18.34M$6.38M$2.17M
Pretax income-$35.38M-$37.69M-$43.10M-$44.04M-$29.00M
Income tax-$1.86M$382,000$1,000$0$0
Net income-$33.52M-$38.07M-$43.10M-$44.04M-$29.00M
EBITDA——-$24.96M-$36.16M-$25.41M
EPS (basic)-0.67-1.16-1.66-2.78-2.38
EPS (diluted)-0.67-1.16-1.66-2.782.38
Weighted avg. shares (diluted)49.96M32.86M25.91M15.87M12.19M
Banking
Loans, net——$36.21M$35.53M$12.09M
Balance sheet
Cash & equivalents$29.03M$46.80M$22.38M$15.50M$58.50M
Short-term investments$103,000$135,000$110,000$101,000$89,000
Receivables$14.68M$14.44M$11.09M$9.36M$4.58M
Inventory$6.74M$3.87M$2.78M$2.33M$1.91M
Current assets$53.41M$66.89M$38.16M$29.15M$66.61M
PP&E, netmay include right-of-use assets (IFRS)$4.86M$4.36M$4.96M$3.79M$1.67M
Goodwill$38.95M$35.93M$35.93M$35.93M$0
Intangibles$39.42M$40.59M$44.34M$46.17M$3.45M
Total assets$147.95M$157.33M$129.13M$119.14M$75.07M
Current liabilities$49.53M$42.66M$19.52M$18.28M$16.43M
Short-term debt—$324,000$643,000$616,000$4.44M
Long-term debt$76.20M$50.97M$35.56M——
Total debt$76.20M$51.29M$36.21M——
Total liabilities$160.05M$142.49M$121.92M$109.82M$28.17M
Shareholders' equity-$12.09M$14.84M$7.21M$9.31M$46.90M
Net debt$47.16M$4.49M$13.83M——
Cash flow statement
Operating cash flow-$2.19M-$18.53M-$21.50M-$34.12M-$22.55M
Capital expenditure$1.16M$1.19M$2.75M$2.79M$896,000
Free cash flow-$3.35M-$19.72M-$24.24M-$36.91M-$23.44M
Investing cash flow-$18.56M-$1.64M-$3.93M-$29.04M-$885,000
Financing cash flow$2.96M$44.60M$32.28M$20.72M$66.50M
Depreciation & amortization——$2.37M$1.74M$1.43M
Stock-based compensation$2.21M$1.73M$665,000$867,000$1.22M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.